new molecular entity

A term describing a chemically unique pharmaceutical that has not yet been marketed in the US in any form

new molecular entity

,

NME

A unique, pharmacologically active product that has never previously been synthesized or used to treat disease.
Mentioned in ?
References in periodicals archive ?
By hiring and retaining creative, best-in-class people, Molecular Devices will continue to design, manufacture, and commercialize analytical instruments, software, and assays to support the scientific success of its customers, regardless of objective: publication, compound hits, lead compounds, new molecular entity, bioassay, biotest, etc.
Tekturna, a new molecular entity (NME), is the first high blood pressure drug approved by FDA that inhibits renin, a kidney enzyme associated with the regulation of blood pressure.
At the same time, the new molecular entity is considered to have fewer deleterious peripheral side effects associated with estrogen-like activity.
Offers an overview of the company's new molecular entity pipeline.
Tyzeka is a new molecular entity, which is a term used by the FDA to describe a medication containing an active substance that has never before been approved for marketing in any form in the United States.
Tapentadol Would be the First New Molecular Entity in the Class of Oral Centrally Acting Analgesics to Enter Medical Practice in Over 25 Years
NU100 is a proprietary recombinant human interferon beta-1b (IFN beta-1b) being developed as a new molecular entity.
a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity (NME) prodrugs, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled, "Methylphenidate-oxoacid conjugates, processes of making and using the same.
Lucentis is a new molecular entity (NME), meaning it contains an active substance that has never before been approved for marketing in any form in the United States.
Phase I studies are mainly conducted to generate information about the toxicity of a New Molecular Entity (NME).
Although new molecular entity approvals in the United States dropped from 26 in 2009 to 21 in 2010, the percentage of NME approvals cleared for marketing versus the number of such filings markedly improved year-over-year.
a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity (NME) prodrugs, announced today that it received a No Objection Letter (NOL) from Health Canada to begin clinical trials in Canada for its lead product candidate KP201 (benzhydrocodone hydrochloride and acetaminophen).